Antigen News and Research

RSS

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death.

3 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.

2 May 2021

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.

30 Apr 2021

Arresting tumor growth for a variety of cancers through T cell engineering

Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues.

30 Apr 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Could COVID-19 rapid antigen tests aid international border control measures?

A recent study has explored the use of rapid antigen testing for COVID-19 at borders to reduce community transmission, and concluded that it would be effective only at lower volumes of passenger traffic.

30 Apr 2021

Researchers review materials used to design biosensors for SARS-CoV-2 detection

The SARS-CoV-2 virus is still causing a dramatic loss of human lives worldwide, constituting an unprecedented challenge for society, public health, and economy, to overcome. Currently, SARS-CoV-2 can be diagnosed in two different ways: i) antigen tests (point-of-care, POC) and ii) molecular tests (nucleic acid, RNA, or PCR-polymerase chain reaction).

30 Apr 2021

Medicare could save nearly $500 million per year by reducing use of low-value preventive care services

A UCLA-led study shows that physicians frequently order preventive medical services for adult Medicare beneficiaries that are considered unnecessary and of "low value" by the U.S. Preventive Services Task Force - at a cost of $478 million per year.

29 Apr 2021

Host protein mimicry of SARS-CoV-2 receptor binding motif

In a new study, structural bioinformatics approaches are employed to investigate the potential mimicry of the receptor-binding motif (RBM) of these three coronaviruses, finding that several proteins from both human and non-human sources were similar to each, with implications regarding the mechanism of infection and tropism of SARS-CoV-2.

29 Apr 2021

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen (PSA) levels to either remain stable or decline.

29 Apr 2021

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States.

29 Apr 2021

Recovered COVID-19 patients show signs of long-term immunity

A study conducted by researchers in the United States has found that most patients who recovered from coronavirus disease 2019 (COVID-19) showed signs of long-lasting immunity against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Apr 2021

Nanobodies may be the key to blocking tick-borne bacterial infection

Tiny molecules called nanobodies, which can be designed to mimic antibody structures and functions, may be the key to blocking a tick-borne bacterial infection that remains out of reach of almost all antibiotics, new research suggests.

28 Apr 2021

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

A new study reports on a set of antibodies from COVID-19 donor serum, which seems to be cross-reactive across multiple Sarbecoviruses, including the very similar SARS-CoV-2, SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV.

28 Apr 2021

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

28 Apr 2021

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

28 Apr 2021

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

A team of scientists recently investigated and compared the efficacy of spike-based and nucleocapsid-based COVID-19 vaccines in mice infected with SARS-CoV-2. Their findings reveal that nucleocapsid-based vaccines are effective in preventing SARS-CoV-2 infection in distal organs, such as the brain.

27 Apr 2021

Antigen News and Research

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Arresting tumor growth for a variety of cancers through T cell engineering

Applications of nanoparticles in combating COVID-19

Could COVID-19 rapid antigen tests aid international border control measures?

Researchers review materials used to design biosensors for SARS-CoV-2 detection

Medicare could save nearly $500 million per year by reducing use of low-value preventive care services

Host protein mimicry of SARS-CoV-2 receptor binding motif

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Recovered COVID-19 patients show signs of long-term immunity

Nanobodies may be the key to blocking tick-borne bacterial infection

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics